Reference data : LOINC code

Filter


Clear filter

Results
108,248 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15359-3 Coagulation dilute Russell viper venom induced actual/Normal RelTime PPP Pt Qn Coag &nbsp; ACTIVE dRVVT actual/normal (normalized LA screen) &nbsp; MIN DefinitionDescription &nbsp; &nbsp; % &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 15359-3 &nbsp; Coag &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Screen dRVVT/normal &nbsp; &nbsp; &nbsp; Y &nbsp; Act/Nor; Clot; Clottable; Coag; Coagulation assay; Control; Dil; Dil Russell Vip Ven; Dilut; dRVV; dRVVT; Hematology; Heme; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; RlTm; Rus; RVV; Screening test for lupus anticoagulant; Tilt tube 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % &nbsp; &nbsp; &nbsp; 0
1536-2 Glucose^45M post dose insulin IV MCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHAL &nbsp; 1536-2 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Glucose 45M p Ins IV SerPl-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; 45M p Ins IV; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente 2.34 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; 0
15360-1 Coagulation dilute Russell viper venom induced actual/Normal PrThr PPP Pt Ord Coag &nbsp; DISCOURAGED dRVVT actual/normal [Presence] in Platelet poor plasma by Coagulation assay &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; Neg;weak pos;moderate pos;pos &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 15360-1 &nbsp; Coag &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 dRVVT Act/Nor PPP Ql &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Act/Nor; Clot; Clottable; Coag; Coagulation assay; Control; Dil; Dil Russell Vip Ven; Dilut; dRVV; dRVVT; Hematology; Heme; Ordinal; Plas; Platelet poor plasma; Point in time; PR; QL; Qual; Qualitative; Random; Rus; RVV; Screen; Screening test for lupus anticoagulant; Tilt tube 2.73 1.0k &nbsp; &nbsp; &nbsp; AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15361-9 Coagulation surface induced.factor substitution^immediately after 1:4 addition of normal plasma Time PPP Pt Qn Coag &nbsp; ACTIVE aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 15361-9 &nbsp; Coag &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 aPTT imm 1:4 NP PPP &nbsp; &nbsp; &nbsp; Y &nbsp; Activated partial thromboplastin time; aPTT; aPTT correction study; Clot; Clottable; Coag; Coagulation assay; Control; Fac; Fact; Hematology; Heme; i; imm 1:4 NP; Little(A)PTT; Mixing studies; Partial Thromboplastin Time; Plas; Platelet poor plasma; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
15362-7 Coagulation surface induced.inhibitor sensitive Time PPP Pt Qn Coag &nbsp; ACTIVE aPTT.inhibitor sensitive in Platelet poor plasma by Coagulation assay &nbsp; MIN DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 15362-7 &nbsp; Coag &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 aPTT Inhib Sens PPP &nbsp; &nbsp; &nbsp; Y &nbsp; Activated partial thromboplastin time; aPTT; aPTT Inhib Sens; Clot; Clottable; Coag; Coagulation assay; Hematology; Heme; Inhib; Inhibit; Little(A)PTT; Partial Thromboplastin Time; Plas; Platelet poor plasma; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
15363-5 Busulfan MCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Busulfan [Mass/volume] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15363-5 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Busulfan SerPl-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Myleran; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
15364-3 Codeine MCnc Meconium Pt Qn &nbsp; &nbsp; DISCOURAGED Codeine [Mass/volume] in Meconium &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15364-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Codeine Mec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Addiction; c260; C300; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Mec; Methylmorphine; Morphine methyl ether; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random 2.52 1.0k &nbsp; &nbsp; &nbsp; AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15365-0 Codeine MCnc Meconium Pt Ord &nbsp; &nbsp; DEPRECATED Deprecated Codeine &nbsp; DEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15365-0 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0 Deprecated Codeine Mec Ql &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Addiction; c260; C300; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Mec; Methylmorphine; Morphine methyl ether; Ordinal; Point in time; PotentialForAbuse; Ql; Qual; Qualitative; Random; Screen 2.36 1.0k &nbsp; &nbsp; &nbsp; AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15366-8 Dextroamphetamine MCnc Urine Pt Qn &nbsp; &nbsp; ACTIVE Dextroamphetamine [Mass/volume] in Urine &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15366-8 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 D-amphet Ur-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Addiction; D-amphet; D-amphetamine; Dexedrine; Dextro-amphetamine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
15367-6 Ganciclovir MCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Ganciclovir [Mass/volume] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15367-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Ganciclovir SerPl-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Cytovene; DRUG/TOXICOLOGY; Drugs; GCV; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Valcyte; Valganciclovir 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
15368-4 Hypoglycemics.sulfonyluric Prid Ser/Plas Pt Nom &nbsp; &nbsp; ACTIVE Hypoglycemics.sulfonyluric [Identifier] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15368-4 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Sulfonyluric Hypogly SerPl &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Sulfonylurea hypoglycemics; Sulfonyluric Hypogly 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
15369-2 Lithium.saliva/Lithium.serum RelRto Ser+Saliva Pt Qn &nbsp; &nbsp; ACTIVE Lithium.saliva/Lithium.serum &nbsp; MIN DefinitionDescription &nbsp; &nbsp; Ratio &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15369-2 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Lithium Sal/SerPl &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Eskalith; Li; Lithane; Lithium Sal; Lithium Sal:Ser:Pl; Oral fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; Relative ratio; Sal; Ser; SerPl; Serum; SR 2.44 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {ratio} &nbsp; &nbsp; &nbsp; 0
1537-0 Glucose^4H post 100 g glucose PO MCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Glucose [Mass/volume] in Serum or Plasma --4 hours post 100 g glucose PO &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHAL &nbsp; 1537-0 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Glucose 4h p 100 g Glc PO SerPl-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; 4h p 100 g Glc PO; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 100 g Glc PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.73 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; 0
15370-0 Morphine MCnc Meconium Pt Qn &nbsp; &nbsp; DISCOURAGED Morphine [Mass/volume] in Meconium &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15370-0 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Morphine Mec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Addiction; c260; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Mec; Morphine sulfate; MS; MSO4; OMPH; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random 2.52 1.0k &nbsp; &nbsp; &nbsp; AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15371-8 Morphine MCnc Meconium Pt Ord &nbsp; &nbsp; DEPRECATED Deprecated Morphine &nbsp; DEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15371-8 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0 Deprecated Morphine Mec Ql &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Addiction; c260; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Mec; Morphine sulfate; MS; MSO4; OMPH; Ordinal; Point in time; PotentialForAbuse; Ql; Qual; Qualitative; Random; Screen 2.36 1.0k &nbsp; &nbsp; &nbsp; AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
15372-6 Nordiazepam MCnc Urine Pt Qn &nbsp; &nbsp; ACTIVE Nordiazepam [Mass/volume] in Urine &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15372-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Nordiazepam Ur-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Calmday; Chlordiazepoxide metabolite; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; UA; UR; Urn; Vegesan 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
15373-4 Phenyltoloxamine MCnc Bld Pt Qn &nbsp; &nbsp; ACTIVE Phenyltoloxamine [Mass/volume] in Blood &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15373-4 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Phenyltoloxamine Bld-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Blood; Comhist; DRUG/TOXICOLOGY; Drugs; Kutrase; Level; Mass concentration; Point in time; Poly-Histine-D; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood 2.7 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
15374-2 Sulfonylurea PrThr Ser/Plas Pt Ord &nbsp; &nbsp; ACTIVE Sulfonylurea [Presence] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15374-2 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Sulfonylurea SerPl Ql &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Sulphonylurea 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
15375-9 Valproate.free MCnc Saliva Pt Qn &nbsp; &nbsp; ACTIVE Valproate Free [Mass/volume] in Saliva (oral fluid) &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 15375-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Valproate Free Sal-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Depakene; Divalproex; DRUG/TOXICOLOGY; Drugs; FR; Level; Mass concentration; Non-protein bound; Oral fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; Sal; VALP; Valproate Free; Valproic acid 2.73 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
15376-7 Spermatozoa.abnormal/Spermatozoa NFr Semen Pt Qn &nbsp; &nbsp; ACTIVE Spermatozoa Abnormal/Spermatozoa in Semen &nbsp; NAM DefinitionDescription &nbsp; &nbsp; % &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; FERT &nbsp; 15376-7 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Sperm Abnorm NFr Smn &nbsp; &nbsp; &nbsp; Y &nbsp; abn; abnorm; Ejaculate; FERTILITY TESTING; Genitourinary; GU; Number Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; Sperm; Sperm Abnorm; URO; Urology 2.79 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % &nbsp; &nbsp; Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; 0
15377-5 Cytomegalovirus Ab PrThr Ser Pt Ord LA &nbsp; ACTIVE Cytomegalovirus Ab [Presence] in Serum by Latex agglutination &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 15377-5 &nbsp; LA &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CMV Ab Ser Ql LA &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CMV; Cytomegalo virus; Cytomgal; HHV-5; Human Herpesvirus-5; ID; Infectious Disease; InfectiousDisease; LAT; Latex agglutination; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR 2.56 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
15378-3 Fungus Prid Isolate Pt Nom Culture &nbsp; ACTIVE Fungus identified in Isolate by Culture &nbsp; NAM DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 15378-3 &nbsp; Culture &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Fungus Islt Cult &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; C&S; Cult; Cultures; Fung; Fungal; Fungi; ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Nominal; Point in time; Random; UniversalLabOrders 2.78 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; 0
15379-1 Haemophilus influenzae B Ag PrThr Urine Pt Ord &nbsp; &nbsp; ACTIVE Haemophilus influenzae B Ag [Presence] in Urine &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 15379-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Haem influ B Ag Ur Ql &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Antigen; Antigens; H flu; H influenza; H influenzae; Haem influ; Haem influ B; Haemoph; HIB; ID; Infectious Disease; InfectiousDisease; Influ; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn 2.56 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
1538-8 Glucose^4H post 100 g glucose PO MCnc Urine Pt Qn &nbsp; &nbsp; ACTIVE Glucose [Mass/volume] in Urine --4 hours post 100 g glucose PO &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHAL &nbsp; 1538-8 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Glucose 4h p 100 g Glc PO Ur-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; 4h p 100 g Glc PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 100 g Glc PO; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.73 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mg/dL &nbsp; &nbsp; &nbsp; 0
15380-9 Leishmania braziliensis Ab.IgG Titr Ser Pt SemiQn &nbsp; &nbsp; ACTIVE Leishmania brasilensis IgG Ab [Titer] in Serum &nbsp; MAJ DefinitionDescription &nbsp; &nbsp; titer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 15380-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 L braziliensis IgG Titr Ser &nbsp; &nbsp; &nbsp; Y &nbsp; ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L brasilensis; L brasiliensis; L braziliensis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr 2.75 1.0k &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {titer} &nbsp; &nbsp; &nbsp; 0
108,248 results found